BMY, MRK And PFE, 3 Drugs Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 17,023 as of Friday, Sept. 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,765 issues advancing vs. 1,183 declining with 200 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Biogen Idec ( BIIB), up 1.3%. Top gainers within the industry include Shire ( SHPG), up 2.2%, Allergan ( AGN), up 1.2% and AstraZeneca ( AZN), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.72 (-1.4%) to $50.90 on light volume. Thus far, 2.0 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $50.80-$51.85 after having opened the day at $51.76 as compared to the previous trading day's close of $51.62.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $86.1 billion and is part of the health care sector. Shares are down 2.9% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.98 (-1.6%) to $58.66 on average volume. Thus far, 6.0 million shares of Merck exchanged hands as compared to its average daily volume of 8.1 million shares. The stock has ranged in price between $58.55-$59.79 after having opened the day at $59.76 as compared to the previous trading day's close of $59.64.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $174.1 billion and is part of the health care sector. Shares are up 19.2% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.32 (-1.1%) to $29.66 on average volume. Thus far, 10.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 22.9 million shares. The stock has ranged in price between $29.56-$29.98 after having opened the day at $29.97 as compared to the previous trading day's close of $29.98.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $192.2 billion and is part of the health care sector. Shares are down 2.1% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing